![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » XANTHUS PHARMACEUTICALS, INC. LICENSES NOVEL CANCER TARGETING AGENTS FROM SCHERING AG
XANTHUS PHARMACEUTICALS, INC. LICENSES NOVEL CANCER TARGETING AGENTS FROM SCHERING AG
September 7, 2006
Xanthus Pharmaceuticals, Inc., a privately held oncology drug development company, announced that the company has acquired from Schering AG, Berlin, the exclusive worldwide rights to develop and commercialize a group of targeted cancer compounds. The lead compound is P2045, which Xanthus intends initially to develop for the treatment of advanced lung cancer. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=29080&full=1)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct